New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Gilead presented early data for combinations of its three mechanisms in NASH, but analysts noted the findings may undercut its lead candidate selonsertib. Plus EASL takeaways for Genfit, NGM and Madrigal.